0001209191-20-031028.txt : 20200520 0001209191-20-031028.hdr.sgml : 20200520 20200520185939 ACCESSION NUMBER: 0001209191-20-031028 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200518 FILED AS OF DATE: 20200520 DATE AS OF CHANGE: 20200520 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Grigoriadis Dimitri E. CENTRAL INDEX KEY: 0001423838 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 20899476 MAIL ADDRESS: STREET 1: 12790 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-05-18 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001423838 Grigoriadis Dimitri E. 12780 EL CAMINO REAL SAN DIEGO CA 92130 0 1 0 0 Chief Research Officer Common Stock 2020-05-18 4 M 0 10000 35.99 A 114741 D Common Stock 2020-05-18 4 S 0 10000 119.98 D 104741 D Common Stock 2020-05-19 4 M 0 10000 35.99 A 114741 D Common Stock 2020-05-19 4 S 0 10000 125.98 D 104741 D Common Stock 2020-05-19 4 S 0 32749 126.7255 D 71992 D Non-Qualified Stock Option 35.99 2020-05-18 4 M 0 10000 35.99 D 2026-02-05 Common Stock 10000 19588 D Non-Qualified Stock Option 35.99 2020-05-19 4 M 0 10000 35.99 D 2026-02-05 Common Stock 10000 9588 D The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.91 to $127.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Option granted February 5, 2016 and vested monthly over four years. /s/ Darin Lippoldt, Attorney-in-Fact 2020-05-20